Loading stock…

ANI Pharmaceuticals, Inc. (ANIP) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

ANI Pharmaceuticals, Inc.

ANIPMarket cap $1.53BPrice $71.5

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

ANI Pharmaceuticals manufactures generic and branded drugs, including rare disease treatments most big pharma companies ignore because the patient pools are too small to bother with. That overlooked niche is exactly where ANI turns steady, defensible profit.

In Bastion Portfolios?

52W Return-25%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+41%10

Revenue Forecast

Rev CAGR (1y)+25%9

Rev CAGR (3y)+14%8

Rev CAGR (5y)+10%7

Earnings Forecast

EPS Growth Y+1+168%10

EPS Growth Y+2+14%7

EPS Growth Y+3+18%8

Quality

Margins

EBIT Margin13%5

Net Income Margin11%6

Free Cash Flow Margin18%8

Debt

Net Debt/EBITDA1.25

Efficiency

ROE19%8

ROA8%8

Earnings Stability66

GEAR+VERY STRONG99

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)710

P/E Ratio (Forward 3y)610

P/BV2.66

EV Multiples

EV/EBITDA Fwd69

EV/EBIT Fwd610

Yield

Free Cash Flow Yield11.3%9

Dividend Yieldna–

Momentum

Short term

1 month return+0%8

3 month return-17%2

YTD return-9%3

Mid term

Price vs 52wHigh74%4

1 year return-22%2

Long term

3 year return+22%4

5 year return+101%7

Risk Shield

Price Risk

Beta0.58

Volatility31%7

Free Cash Flow

Free Cash Flow Margin18%8

Free Cash Flow Yield11.3%9

Quality

ROCE11%6

Earnings Stability66

Net Debt/EBITDA1.25

02Growth

Is it actually growing, and how fast?

ANIPANI Pharmaceuticals

Revenue FY25$883M

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+41%10

Revenue, next 1Y+25%9

Revenue, next 3Y, CAGR+14%8

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+168%10

EPS growth, FY27E+14%7

EPS growth, FY28E+18%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue grew 41%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 14%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 18%/yr vs revenue 14%/yr).

WATCH

Revenue grew 41%/yr over the last 3 years; forecasts see it cooling to 14%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK30 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+0%8

3-month return-17%2

YTD return-9%3

MID & LONG-TERM▾SCORE

% of 52-week high74%4

1-year return-22%2

3-year return+22%4

5-year return+101%7

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+0%).

WATCH

Average long-term results. Multi-year returns are middling (+22% over three years and +101% over five), roughly average for the market.

WEAKNESSES

It's down 22% over the past year, now 26% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-17%) and so far this year (-9%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on ANI Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ANIPANI Pharmaceuticals

Revenue FY25$883M

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+41%10

Revenue, next 1Y+25%9

Revenue, next 3Y, CAGR+14%8

Revenue, next 5Y, CAGR+10%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+168%10

EPS growth, FY27E+14%7

EPS growth, FY28E+18%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue grew 41%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 14%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 10%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 18%/yr vs revenue 14%/yr).

WATCH

Revenue grew 41%/yr over the last 3 years; forecasts see it cooling to 14%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK30 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+0%8

3-month return-17%2

YTD return-9%3

MID & LONG-TERM▾SCORE

% of 52-week high74%4

1-year return-22%2

3-year return+22%4

5-year return+101%7

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+0%).

WATCH

Average long-term results. Multi-year returns are middling (+22% over three years and +101% over five), roughly average for the market.

WEAKNESSES

It's down 22% over the past year, now 26% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-17%) and so far this year (-9%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on ANI Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community